What the study found
Researchers at the University of Hong Kong examined city-wide medical records for more than 120,000 people aged 60 and older who had osteoporosis or a fragility fracture between 2005 and 2020. Those who took nitrogen-containing bisphosphonates — alendronate, ibandronate, risedronate and zoledronate — were 16 percent less likely to develop Alzheimer's disease or related dementias than patients who received no osteoporosis treatment.
Compared with people who took other osteoporosis medicines, the difference was 24 percent. The link was strongest among women and among patients who had broken a hip.
How large the effect is
Over five years, the absolute reduction in dementia risk was about 2.1 percentage points. The authors calculated that 48 patients would need to take the drugs for five years to prevent one case. That is a modest effect for one person and a large one across a population, given how common both conditions are in older adults.
Careful reading required
This is an observational study of records, not a randomised trial. People who take osteoporosis drugs may differ from those who do not in ways the analysis cannot fully capture. They see doctors more often, for example, and they are being treated for a condition that the same team has already shown to be an independent risk factor for dementia.
Bisphosphonates are widely used, inexpensive and well studied in older adults, which makes them an attractive candidate for drug repurposing. If a trial confirms the association, a pill already taken for bones could become part of dementia prevention. Until then the finding is a hypothesis with a very large dataset behind it: a reason to study, not a reason to prescribe.
The researchers controlled for age, sex, income, other prescriptions and existing diagnoses, and they compared users with two different control groups to reduce bias. Residual confounding cannot be ruled out in either comparison.